Gemini Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended and Six Month Ended June 30, 2021
August 12, 2021 at 04:30 pm IST
Gemini Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter ended and six month ended June 30, 2021. For the quarter, the company reported loss from operations of $16,320,000 compared to $6,666,000 a year ago. Net loss and comprehensive loss was $16,447,000 compared to $6,773,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.38 compared to $0.44 a year ago.
For the six months, the company reported loss from operations of $32,810,000 compared to $16,297,000 a year ago. Net loss and comprehensive loss was $35,495,000 compared to $16,519,000 a year ago. Net loss per share attributable to common stockholders, basic and diluted was $0.94 compared to $1.11 a year ago.